EPAS1 and ischemic cardiomyopathy: Further studies with HIF2α protein small molecule agonists should verify whether these molecules affect the cellular expression of IL-6 and reduce MIRI to provide a new target for the prevention and treatment of ischemic cardiomyopathy.